Curis (CRIS) Receivables - Net (2010 - 2025)
Curis' (CRIS) quarterly Receivables - Net came in at $3.2 million in Q3 2025, up 8.9% YoY from $3.0 million in Q3 2024, and up 17.84% on a QoQ basis from $2.8 million in Q2 2025.
Curis (CRIS) Receivables - Net (2010 - 2025) Analysis & Trends
Curis (CRIS) has 16 years of Receivables - Net data on file, last reported at $3.2 million in Q3 2025.
- Quarterly Receivables - Net rose 8.9% year-over-year to $3.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $3.2 million (up 8.9% YoY) and the FY2024 annual result came in at $3.3 million, up 19.86% from the prior year.
- Receivables - Net improved to $3.2 million in Q3 2025, from $2.8 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $3.3 million in Q4 2024 to a low of $2.1 million in Q1 2022.
- A 5-year average of $2.7 million and a median of $2.8 million in 2025 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2021 — Receivables - Net slipped 12.92% — and 2024, when it climbed 19.86%.
- Tracing CRIS's Receivables - Net over 5 years: stood at $3.2 million in 2021, then dropped by 7.72% to $3.0 million in 2022, then dropped by 6.08% to $2.8 million in 2023, then climbed by 19.86% to $3.3 million in 2024, then dropped by 3.17% to $3.2 million in 2025.
- The last three Receivables - Net figures came in at $3.2 million (Q3 2025), $2.8 million (Q2 2025), and $2.3 million (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 3.24 Mn |
| Sep 30, 2025 | 3.24 Mn |
| Jun 30, 2025 | 2.75 Mn |
| Jun 30, 2025 | 2.75 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.32 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Dec 31, 2024 | 3.35 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Jun 30, 2024 | 2.55 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Mar 31, 2024 | 2.15 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Dec 31, 2023 | 2.79 Mn |
| Sep 30, 2023 | 2.85 Mn |
| Sep 30, 2023 | 2.85 Mn |
| Jun 30, 2023 | 2.39 Mn |
| Jun 30, 2023 | 2.39 Mn |